Avalo Therapeutics (AVTX) Chief Legal Officer details ESPP share deal

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. reported an equity transaction by its Chief Legal Officer on December 10, 2025. The officer reported a transaction in Avalo common stock coded “F” involving 1,016 shares at a price of $4.10 per share. After this transaction, the officer beneficially owns 3,634 shares of Avalo common stock. A note explains that these 3,634 shares were acquired under Avalo’s Employee Stock Purchase Plan as part of the reported transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

VARKI PAUL

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/10/2025		F		1,016	D	$4.1	3,634(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 3,634 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction.

	/s/ Christopher Sullivan, by Power of Attorney	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transaction did Avalo Therapeutics (AVTX) report?

Avalo Therapeutics reported that its Chief Legal Officer completed a transaction in the company’s common stock on December 10, 2025, as disclosed in a beneficial ownership filing.

How many Avalo Therapeutics (AVTX) shares were involved and at what price?

The reported transaction involved 1,016 shares of Avalo common stock at a price of $4.10 per share in a transaction coded “F.”

How many Avalo Therapeutics (AVTX) shares does the officer own after the transaction?

Following the reported transaction, the officer beneficially owns 3,634 shares of Avalo Therapeutics common stock.

Is the Avalo Therapeutics (AVTX) transaction connected to an employee stock purchase plan?

Yes. The filing notes that the 3,634 shares beneficially owned after the transaction include shares acquired under Avalo’s Employee Stock Purchase Plan as part of this reporting transaction.

What is the reporting person’s role at Avalo Therapeutics (AVTX)?

The reporting person is identified as an officer of Avalo Therapeutics, serving as the company’s Chief Legal Officer.

Was this Avalo Therapeutics (AVTX) Form 4 filed by more than one reporting person?

No. The filing indicates that it is a Form filed by one reporting person, not a joint or group filing.